{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:44:01Z","timestamp":1789721041782,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.ctrv.2007.09.001","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T18:10:55Z","timestamp":1205345455000},"page":"49-60","source":"Crossref","is-referenced-by-count":47,"title":["Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Roberto","family":"Stasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Buccisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2007.09.001_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2007.09.001_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/canjclin.52.6.363","article-title":"The difficult problem of acute myeloid leukemia in the older adult","volume":"52","author":"Stone","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2007.09.001_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood.V62.1.124.124","article-title":"Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies","volume":"62","author":"Andrews","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib4","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.141.8.2797","article-title":"Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells","volume":"141","author":"Simmons","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib6","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C","article-title":"The sialoadhesin CD33 is a myeloid-specific inhibitory receptor","volume":"29","author":"Ulyanova","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib7","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1073\/pnas.091097198","article-title":"Surface expression and function of p75\/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells","volume":"98","author":"Vitale","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2007.09.001_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF01534423","article-title":"Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias","volume":"39","author":"McGraw","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2007.09.001_bib9","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"van Der Velden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0145-2126(01)00084-4","article-title":"Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells","volume":"25","author":"Balaian","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0301-472X(03)00044-4","article-title":"The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and\/or ZAP-70 expression","volume":"31","author":"Balaian","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","article-title":"Differences in CD33 intensity between various myeloid neoplasms","volume":"118","author":"Jilani","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib14","first-page":"634","article-title":"In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study","volume":"89","author":"Leone","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.09.001_bib15","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1021\/ja00245a050","article-title":"Calicheamicins, a novel family of antitumor antibiotics 1 Chemistry and partial structure of calicheamicin \u03b31I","volume":"109","author":"Lee","year":"1987","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ctrv.2007.09.001_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ctrv.2007.09.001_bib17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2007.09.001_bib18","first-page":"3336","article-title":"Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics","volume":"53","author":"Hinman","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0968-0896(00)82187-2","article-title":"Regulation of apoptosis in leukemic cells by analogs of dynemicin A","volume":"2","author":"Hiatt","year":"1994","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ctrv.2007.09.001_bib20","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1021\/bi992227g","article-title":"DNA bending is a determinant of calicheamicin target recognition","volume":"39","author":"Salzberg","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2007.09.001_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/jmbi.1996.0718","article-title":"Solution structure of the calicheamicin gamma 1I-DNA complex","volume":"265","author":"Kumar","year":"1997","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib22","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","article-title":"Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3","volume":"101","author":"Amico","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2004-07-2784","article-title":"Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity","volume":"105","author":"Walter","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib24","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib25","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood-2003-11-3825","article-title":"The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin","volume":"103","author":"Walter","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib26","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy","volume":"109","author":"Walter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","article-title":"Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity","volume":"18","author":"Jedema","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exphem.2005.10.003","article-title":"Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells","volume":"34","author":"Rutella","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.leu.2404477","article-title":"The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells","volume":"21","author":"ten Cate","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.21.15.1175.33890","article-title":"Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin","volume":"21","author":"Korth-Bradley","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ctrv.2007.09.001_bib32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/00912700122012751","article-title":"Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse","volume":"41","author":"Dowell","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib33","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib34","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib35","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/sj.leu.2402677","article-title":"Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)","volume":"16","author":"Larson","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib36","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.09.001_bib37","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1080\/1042819021000016078","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia","volume":"43","author":"Roboz","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.09.001_bib39","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood.V99.12.4343","article-title":"Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib40","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","article-title":"Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Leukemia Groups","volume":"19","author":"Amadori","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2004.04.011","article-title":"Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older","volume":"29","author":"Nabhan","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-0609.2005.00623.x","article-title":"Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"76","author":"van der Heiden","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib44","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","article-title":"Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas","volume":"45","author":"Piccaluga","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2007.09.001_bib45","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","article-title":"Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis","volume":"101","author":"Zwaan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000075606","article-title":"Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Reinhardt","year":"2004","journal-title":"Onkologie"},{"key":"10.1016\/j.ctrv.2007.09.001_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2407-6-172","article-title":"Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed\/refractory myeloid leukemia","volume":"6","author":"Brethon","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2007.09.001_bib48","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","article-title":"Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia","volume":"50","author":"Cortes","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-002-0546-z","article-title":"Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia","volume":"51","author":"Alvarado","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0145-2126(03)00021-3","article-title":"Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia","volume":"27","author":"Apostolidou","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib52","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cncr.11239","article-title":"Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.09.001_bib53","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(03)00022-5","article-title":"Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib54","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib55","first-page":"950","article-title":"Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups","volume":"89","author":"Amadori","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.09.001_bib56","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.leukres.2005.02.005","article-title":"Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia","volume":"29","author":"Chevallier","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.2007.06646.x","article-title":"Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients","volume":"138","author":"Clavio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00277-007-0272-z","article-title":"Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience","volume":"86","author":"Specchia","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.leukres.2004.01.009","article-title":"First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients","volume":"28","author":"Piccaluga","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.13.13","article-title":"The addition of Gemtuzumab Ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1521-6926(03)00042-2","article-title":"Expression of cell-surface antigens in acute promyelocytic leukaemia","volume":"16","author":"Paietta","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.leu.2403807","article-title":"Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells","volume":"19","author":"Takeshita","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2007.09.001_bib63","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1182\/blood-2004-04-1550","article-title":"Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia","volume":"104","author":"Lo-Coco","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2141.2001.03091.x","article-title":"Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676)","volume":"115","author":"Petti","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib65","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (mylotarg) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib66","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2004.01.004","article-title":"Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies","volume":"28","author":"Tsimberidou","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib67","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/cncr.22524","article-title":"Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.09.001_bib68","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1345\/aph.1C511","article-title":"Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions","volume":"37","author":"Giles","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ctrv.2007.09.001_bib69","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.09.001_bib70","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.09.001_bib71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001622-200003000-00001","article-title":"Veno-occlusive disease of the liver","volume":"12","author":"Bearman","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2007.09.001_bib72","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.11791","article-title":"Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia","volume":"98","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2007.09.001_bib73","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2007.09.001_bib74","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","article-title":"Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg)","volume":"2","author":"McDonald","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ctrv.2007.09.001_bib75","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2007.09.001_bib76","first-page":"1114","article-title":"Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy","volume":"87","author":"Giles","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.09.001_bib77","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","article-title":"Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure","volume":"103","author":"Versluys","year":"2004","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:02:33Z","timestamp":1684285353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737207001351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0305737207001351"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2007.09.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}